BioMark Diagnostics Inc
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for wo… Read more
BioMark Diagnostics Inc (BMKDF) - Net Assets
Latest net assets as of December 2024: $-1.10 Million USD
Based on the latest financial reports, BioMark Diagnostics Inc (BMKDF) has net assets worth $-1.10 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($876.63K) and total liabilities ($1.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.10 Million |
| % of Total Assets | -125.24% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -512.0% |
| Growth Volatility | 272.42 |
BioMark Diagnostics Inc - Net Assets Trend (2014–2024)
This chart illustrates how BioMark Diagnostics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioMark Diagnostics Inc (2014–2024)
The table below shows the annual net assets of BioMark Diagnostics Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-03-31 | $-609.61K | +46.97% |
| 2023-03-31 | $-1.15 Million | -80.84% |
| 2022-03-31 | $-635.69K | -703.72% |
| 2021-03-31 | $-79.09K | +81.99% |
| 2020-03-31 | $-439.13K | +63.99% |
| 2019-03-31 | $-1.22 Million | -35.41% |
| 2018-03-31 | $-900.43K | +15.45% |
| 2017-03-31 | $-1.07 Million | -92.15% |
| 2016-03-31 | $-554.28K | -474.61% |
| 2015-03-31 | $147.96K | +70.23% |
| 2014-03-31 | $86.92K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioMark Diagnostics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1343534500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.14 Million | % |
| Other Comprehensive Income | $350.00K | % |
| Other Components | $2.35 Million | % |
| Total Equity | $-609.61K | 100.00% |
BioMark Diagnostics Inc Competitors by Market Cap
The table below lists competitors of BioMark Diagnostics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taiwan Thick-Film Ind
TWO:6246
|
$8.41 Million |
|
Gauzy Ltd. Ordinary Shares
NASDAQ:GAUZ
|
$8.41 Million |
|
Gia Lai Electricity JSC
VN:GEG
|
$8.41 Million |
|
Willowglen MSC Bhd
KLSE:0008
|
$8.41 Million |
|
Havila Shipping ASA
OL:HAVI
|
$8.40 Million |
|
Promimic AB
ST:PRO
|
$8.40 Million |
|
Shengfeng Development Limited Class A Ordinary Shares
NASDAQ:SFWL
|
$8.40 Million |
|
Garuda Maintenance Facility AeroAsia Tbk PT
JK:GMFI
|
$8.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioMark Diagnostics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,149,575 to -609,606, a change of 539,969.
- Net loss of 1,427,385 reduced equity.
- New share issuances of 1,541,874 increased equity.
- Other comprehensive income decreased equity by 8,126.
- Other factors increased equity by 433,606.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.43 Million | -234.15% |
| Share Issuances | $1.54 Million | +252.93% |
| Other Comprehensive Income | $-8.13K | -1.33% |
| Other Changes | $433.61K | +71.13% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BioMark Diagnostics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-03-31 | $0.02 | $0.18 | x |
| 2015-03-31 | $0.01 | $0.18 | x |
| 2016-03-31 | $-0.01 | $0.18 | x |
| 2017-03-31 | $-0.02 | $0.18 | x |
| 2018-03-31 | $-0.01 | $0.18 | x |
| 2019-03-31 | $-0.02 | $0.18 | x |
| 2020-03-31 | $-0.01 | $0.18 | x |
| 2021-03-31 | $0.00 | $0.18 | x |
| 2022-03-31 | $-0.01 | $0.18 | x |
| 2023-03-31 | $-0.01 | $0.18 | x |
| 2024-03-31 | $-0.01 | $0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioMark Diagnostics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -874.52%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-195.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -208.24% | 0.00% | 0.00x | 1.06x | $-189.69K |
| 2015 | -1943.18% | 0.00% | 0.00x | 1.56x | $-2.89 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.35 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-608.92K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-636.70K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-423.68K |
| 2020 | 0.00% | -461.59% | 0.41x | 0.00x | $-1.17 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.09 Million |
| 2022 | 0.00% | -3309.36% | 0.03x | 0.00x | $-1.39 Million |
| 2023 | 0.00% | -1200.21% | 0.21x | 0.00x | $-1.73 Million |
| 2024 | 0.00% | -874.52% | 0.15x | 0.00x | $-1.37 Million |
Industry Comparison
This section compares BioMark Diagnostics Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioMark Diagnostics Inc (BMKDF) | $-1.10 Million | -208.24% | N/A | $8.41 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |